Skip to main content

Advertisement

Table 2 Univariate comparison of demographic and tumor-related characteristics between pCR and non-pCR patients

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Characteristic Patients with pCR, number (%) or median (IQR) Patients with non-pCR, number (%) or median (IQR) P value
Overall population 16 (40) 24 (60) --
Age (years), median 45.5 (35.5–51.5) 49.5 (34.3–53.0) 0.97
BMI (kg/m2), median 25.7 (23.3–29.6) 27.3 (24.2–31.0) 0.49
Race    0.63
 White 15 (93.8) 20 (83.3)
 Black/Asian/Hispanic 1 (6.2) 4 (16.7)
Charlson comorbidity index    0.75
 <2 (mild) 7 (43.8) 9 (37.5)
 ≥2 (moderate–high) 9 (56.2) 15 (62.5)
Menopausal status    1.00
 Premenopausal 9 (56.2) 14 (58.3)
 Postmenopausal 7 (43.8) 10 (41.7)
AJCC clinical stageb    0.12
 II 11 (68.8) 10 (41.7)
 III 5 (31.2) 14 (58.3)
ER/PR statusb    0.02
 Positive 5 (31.2) 17 (70.8)
 Negative 11 (68.8) 7 (29.2)
Lymphovascular invasion    0.21
 Absent 15 (93.8) 18 (75.0)
 Present 1 (6.2) 6 (25.0)
Nuclear grade    0.33
 Grade 1/2 4 (25.0) 10 (41.7)
 Grade 3 12 (75.0) 14 (58.3)
Neoadjuvant regimen    1.00
 AC/TH 13 (81.3) 20 (83.3)
 Othera 3 (18.7) 4 (16.7)
Operative approachb    0.09
 BCS + XRT 8 (50.0) 5 (20.8)
 Mastectomy ± XRT 8 (50.0) 19 (79.2)
  1. aOther included carboplatin/taxotere/trastuzumab and taxotere/cyclophosphamide/trastuzumab. bIncluded in multivariable logistic regression analysis to determine independent correlates to pCR. pCR pathologic complete response, BMI body mass index, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, BCS breast-conserving surgery, XRT radiotherapy